Toxicity, Antitumor and Chemosensitizing Effects of 3-Chloroprocainamide

References

• Horsman M R, Brown D M, Lemmon M J, Brown J M, Lee W W. Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys 1986; 12: 1307–10
   PubMed Web of Science ®Google Scholar
• Harrington R A, Hamilton C W, Brogben R N, Linkewich J A, Romankiewicz J A, Heel R C. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983; 25: 451–549
   PubMed Web of Science ®Google Scholar
• Kjellén E, Wennerberg J, Pero R W. Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck. Br J Cancer 1989; 59: 247–50
   PubMed Web of Science ®Google Scholar
• Lybak S, Kjellén E, Wennerberg J, Pero R W. Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1990; 19: 1419–24
   PubMed Web of Science ®Google Scholar
• Werning J W, Stepnick D W, Jafri A, Megerian C A, Antunez A R, Zaidi S I. Metoclopramide enhances the effect of photodynamic therapy on xenografted human squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995; 121: 783–9
   PubMedGoogle Scholar
• Johnsson A, Kjellén E, Wennerberg J, Pero R W. Metoclopramide as a modulator of cisplatin: effects on pharmacokinetics and cisplatin-DNA adducts in tumor and normal tissue. Anticancer Drugs 1996; 7: 483–8
   PubMed Web of Science ®Google Scholar
• Hua J, Olsson A, Sheng Y, Pero R W. Acidic and neutralized metoclopramide formulations sensitize ionizing radiation induced cytotoxicity in a human lung adenocarcinoma xenografted to Scid mice. Anticancer Drugs 1995; 6: 451–5
   PubMed Web of Science ®Google Scholar
• Olsson A, Hua J, Sheng Y, Pero R W. Neutral metoclopramide induces tumor cytotoxicty and sensitizes ionizing radiation of a human lung and an adeno-type 12 virus induced mouse sarcoma in mice. Acta Oncol 1997; 36: 321–8
   Web of Science ®Google Scholar
• Salford L G, Pero R W, Aas A T, Brun A. Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) treatment of brain tumors in the rat. Anticancer Drugs 1992; 3: 267–72
   PubMed Web of Science ®Google Scholar
• Kjellén E, Pero R W, Brun E, et al. A phase I/II evaluation of metoclopramide as a radiosensitiser in patients with inoperable squamous cell carcinoma of the lung. Eur J Cancer 1995; 31: 2196–202
   Google Scholar
• van de Waterbeemd H, Carrupt P A, Testa B. Similarities of pharmcaphoric patterns revealed by the MEP of metoclopramide, molindone and piqamine D-2 receptor antagonists. J Mol Graph 1986; 4: 51–5
   Google Scholar
• Pero W R, Olsson A, Simanaitis M, Amiri A, Adersen I. Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, Sensamide and neu-Sensamide. Pharmacol Toxicol 1997; 80: 231–9
   PubMedGoogle Scholar
• Pero W R, Olsson A, Sheng Y, et al. Progress in identifying clinical relevance of inhibition, stimulation and measurement of poly ADP-ribosylation. Biochimie 1995; 77: 385–93
   PubMed Web of Science ®Google Scholar
• Pero W R, Olsson A, Amiri A, Chaplin D. Multiple mechanism of action of the benzamides and nicotinamides as sensiters of radio- and chemotherapies. Opportunities for drug design. Cancer Detect Prev 1997, in press
   Google Scholar
• Lybak S, Wennerberg J, Kjellén E, Pero R W. Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Anticancer Drugs 1991; 2: 375–82
   PubMed Web of Science ®Google Scholar
• Goth A. Medical pharmacology. Tenth editon, A Goth. CV Mosby. 1981; 282
   Google Scholar
• Attia M A, Weiss D W. Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 1966; 26: 1787–800
   PubMed Web of Science ®Google Scholar
• Lesser M L, Braun H L, Helson L. Statistical methods for measuring and comparing treatment efficacies: application to nude mice experiment. Exp Cell Biol 1980; 48: 126–37
   PubMedGoogle Scholar
• Begg A C. Analysis of growth delay data potential pitfalls. Br J Cancer 1980; 41(Suppl)93–7
   Google Scholar
• Szumiel I, Wlodek D, Johnson K J, Sundell-Bergman S. ADP-ribosylation and post-irradiation cellular recovery in two strains of L5178Y cells. Br J Cancer 1984; 6(Suppl)33–8
   Google Scholar
• Berger M R, Bischoff H, Fritschi E, et al. Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2′-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep 1985; 69: 1415–24
   PubMedGoogle Scholar
• Berger M R, Schmahl D. On the long-term toxic risk of dinaline. Cancer Lett 1991; 60: 237–43
   PubMed Web of Science ®Google Scholar
• Miyakoshi J, Oda W, Inagaki C. Effects of m-aminobenzamide on the response of Chinese hamster cells to hyperthermia and/or radiation. Radiat Res 1985; 102: 359–66
   PubMed Web of Science ®Google Scholar
• Raaphorst G P, Azzam E I. Poly(ADP-ribose) synthetase inhibitors increase radiation and thermal sensitivity but do not affect thermotolerance. Radiat Res 1988; 116: 442–52
   PubMed Web of Science ®Google Scholar
• Kjellén E, Pero R W, Nilsson P. Comparison of low dose nicotinamide versus benzamide, administered per os, as radiosensitizers in a C3H mammary carcinoma. Radiother Oncol 1988; 12: 327–31
   PubMed Web of Science ®Google Scholar
• Horsman M R, Wood P J, Chaplin D J, Brown J M, Overgarrd J. The potentiation of radiation damadge by nicotinamide in the SCCVII tumor in vivo. Radiother Oncol 1990; 18: 49–57
   PubMed Web of Science ®Google Scholar
• Brown J M, Lemmon M J, Horsman M R, Lee W W. Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. Int J Radiat Biol 1991; 59: 739–48
   PubMed Web of Science ®Google Scholar
• el-Beltagi H M, Martens A C, Lelieveld P, Haroun E A, Hagenbeek A. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells-preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res 1993; 53: 3008–14
   PubMed Web of Science ®Google Scholar
• Horsman M R, Chaplin D J. Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide. Br J Cancer 1994; 69: 648–54
   PubMed Web of Science ®Google Scholar
• Olsson A, Sheng Y, Kjellén E, Pero R W. In vivo tumor measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis 1995; 16: 1029–35
   PubMed Web of Science ®Google Scholar
• Schaider H, Haberkorn U, Berger M R, Oberdorfer F, Morr I, van Kaick G. Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Eur J Nucl Med 1996; 23: 55–60
   PubMedGoogle Scholar
• Horsman M R. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumor. A review. Acta Oncol 1995; 34: 571–8
   PubMed Web of Science ®Google Scholar
• Lybak S, Pero R W. The benzamide derivative metoclopramide causes DNA damge and inhibition of DNA repair in huma peripheral mononuclear leucocytes at clinically relevant doses. Carcinogenesis 1991; 12: 1613–7
   PubMed Web of Science ®Google Scholar
• FASS. Medical drugs in Sweden. 1996
   Google Scholar
• Hanocq M, Topart J, van Damme M, Molle L. Determination des constantes d'ionisation de quelques N-(diethylamino-2-ethyl) benzamides substitues. J Pharm Belg 1973; 28: 649–62
   PubMedGoogle Scholar
• Rotrosen J, Stanley M, Lautin A, Wazer D, Gershon S. Discrimination of functionally heterogeneous receptor subpopulations: Antipsychotic and antidopaminergic properties of metoclopramide. Psychopharmacol Bull 1981; 17: 110–3
   PubMedGoogle Scholar
• Manor D, Sadeh M. Muscle fibre necrosis induced by intramuscular injection of drugs. Br J Exp Pathol 1989; 70: 457–62
   PubMedGoogle Scholar